More than 30 oral and poster presentations at the American Association for Cancer Research Annual Meeting 2024 will be simultaneously published as articles in AACR journals, reflecting the high number of meritorious abstracts submitted for presentation at the meeting. The studies below, listed by day with session/presentation details, will be concurrently published in the AACR journals noted. Direct links to the journal articles will be available here as they are published.

---

SATURDAY, APRIL 6

ORAL PRESENTATION

Bridging pre-clinical drug screening with patient molecular profiles for biomarker discovery and drug development

Session: ED35 – Development and Evaluation of Drug Response Predictors for Precision Oncology, 8 – 9:30 a.m. PT*
Location: Ballroom 6 A, Upper Level, Convention Center
Journal: Cancer Research

Mapping the spatial architecture of the TME in lung tumour evolution

Session: ED44 – Host Predisposing Stroma in Cancer Development and Progression, 10 – 11:30 a.m. PT*
Location: Ballroom 6 A, Upper Level, Convention Center
Journal: Cancer Discovery

(*requires Educational Program Pass)

---

SUNDAY, APRIL 7

ORAL PRESENTATION

CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Long-term follow-up and translational data from the phase 1 COBALT-RCC study

Session: CTPL01 – Beyond Immune Checkpoint Inhibition: Novel Immunotherapy Strategies, 1 – 3 p.m. PT
Location: Hall GH, Ground Level, Convention Center
Journal: Cancer Discovery

---

MONDAY, APRIL 8

ORAL PRESENTATIONS

Spatial encoding of immune response and clinical outcome in the breast cancer tumor microenvironment

Session: PL03 – Profiling Tumor Ecosystems in Native Tissue Context, 8 – 10 a.m. PT
Location: Hall GH, Ground Level, Convention Center
Journal: Cancer Discovery

KRYSTAL-1: Pooled phase 1/2 efficacy and safety of adagrasib (MRTX849) in combination with cetuximab in patients with metastatic colorectal cancer (CRC) harboring a KRASG12C mutation

Session: CTPL03 – Advances in Targeted Therapy, 10:15 a.m. – 12:15 p.m. PT
Location: Ballroom 20 AB, Upper Level, Convention Center
Journal: Cancer Discovery

NST-628 is a novel, potent, fully brain-penetrant MAPK pathway molecular glue that inhibits RAS- and RAF-driven cancers

Session: DDT03 – New Drugs on the Horizon: Part 3, 10:15 a.m. – 11:45 a.m. PT
Location: Ballroom 20 CD, Upper Level, Convention Center
Journal: Cancer Discovery

NCI Director’s Address

Session: LE02 – NCI Director’s Address and Fireside Chat, 2:15 p.m. – 3:15 p.m. PT
Location: Ballroom 6 A, Upper Level, Convention Center
Journal: Cancer Discovery

Randomized placebo-controlled, biomarker-stratified phase 1b microbiome modulation trial for metastatic melanoma demonstrates impact of antibiotic pre-conditioning regimen on the microbiome and immunity

Session: CTMS02 – Advances in Immunotherapy, 2:30 p.m. – 4:30 p.m. PT
Location: Hall GH, Ground Level, Convention Center
Journal: Cancer Discovery

PVRL2 suppresses antitumor immune responses through PVRIG- and TIGIT-independent pathways

Session: LBMS01 – Minisymposium: Late-Breaking Research, 2:30 p.m. – 4:30 p.m. PT
Location: Room 16, Mezzanine Level, Convention Center
Journal: Cancer Immunology Research

POSTER PRESENTATIONS

Impact of circulating tumor cell-expressed prostate-specific membrane antigen and prostate-specific antigen transcripts in various stages of prostate cancer

Session: LBPO.CL01 – Late-Breaking Research: Clinical Research 1, 9 a.m. – 12:30 p.m. PT
Location: Poster Section 51, Board 21, Presentation 110
Journal: Clinical Cancer Research

Cancer associated fibroblast – tumor cell crosstalk enhances epithelial to mesenchymal transition and promotes a classical to basal switch in human pancreatic ductal adenocarcinoma

Session: PO.TB11.12 -Pancreatic Cancer Microenvironment, 9 a.m. – 12:30 p.m. PT
Location: Poster Section 11, Board 2, Presentation 1577
Journal: Cancer Research

Dearth of smoking-induced mutations in oncogene-driven NSCLCs despite smoking exposure

Session: PO.MCB08.02 – Genomic Characterization of Cancers and Cancer Subgroups, 9 a.m. – 12:30 p.m. PT
Location: Poster Section 17, Board 3, Presentation 1748
Journal: Cancer Research

Low exposures to amphibole or serpentine asbestos in germline Bap1-mutant mice induce mesotheliomacharacterized by an immunosuppressive tumor microenvironment

Session: PO.TB02.01 – Chemical, Environmental, and Virus-Induced Carcinogenesis, 9 a.m. – 12:30 p.m. PT
Location: Poster Section 7, Board 6, Presentation 1468
Journal: Cancer Research Communications

Actívatexto: Feasibility and acceptability of a mobile intervention that promotes smoking cessation and physical activity among Latinos

Session: PO.PR01.04 – Health Disparities Across the Cancer Continuum, 9 a.m. – 12:30 p.m. PT
Location: Poster Section 31, Board 21, Presentation 2154
Journal: Cancer Research Communications

Inflammation mediated expression of integrin αvβ3 potentiates KRAS driven PDAC oncogenesis

Session: PO.TB11.03 – The Extracellular Matrix in Cancer, 9 a.m. – 12:30 p.m. PT
Location: Poster Section 12, Board 6, Presentation 4267
Journal: Cancer Research

Sensitizing immunotherapy-refractory prostate cancer to immune checkpoint blockade therapy with optimized ketogenic diet regimens

Session: PO.IM02.02 – Epigenetic Regulation of Tumor Immunity, 1:30 p.m. – 5 p.m. PT
Location: Poster Section 3, Board 12, Presentation 2638
Journal: Cancer Research

Palbociclib as a novel therapeutic for desmoplastic small round cell tumor

Session: PO.TB06.02 – Pediatric Cancer Genomics and Epigenomics, 1:30 p.m. – 5 p.m. PT
Location: Poster Section 11, Board 5, Presentation 2849
Journal: Cancer Research

First disclosure of XRD-0394, a novel dual ATM/DNA-PK inhibitor, that potently radiosensitizes and potentiates PARP and topoisomerase inhibitors

Session: LBPO.ET02 – Late-Breaking Research: Experimental and Molecular Therapeutics 2, 1:30 p.m. – 5 p.m. PT
Location: Poster Section 52, Board 27, Presentation 181
Journal: Molecular Cancer Therapeutics

---

TUESDAY, APRIL 9

ORAL PRESENTATIONS

Metastasis aggressiveness: A function of metabolite signaling

Session: PL04 – Evolution of the Genome, Microenvironment, and Host through Metastasis, 8 – 10 a.m. PT
Location: Hall GH, Ground Level, Convention Center
Journal: Cancer Discovery

Discovery of RMC-6236, a tri-complex RAS (ON)multi-selective inhibitor

Session: ADT06 – KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology, 12:30 – 2 p.m. PT
Location: Ballroom 20 AB, Upper Level, Convention Center
Journal: Cancer Discovery

The Cancer Moonshot: Opportunities to Fulfill the Vision of the National Cancer Plan – Dedicated to the Memory of Senator Dianne Feinstein

Session: DC14 – The Cancer Moonshot: Opportunities to Fulfill the Vision of the National Cancer Plan – Dedicated to the Memory of Senator Dianne Feinstein, 2:30 – 4 p.m. PT
Location: Room 1, Upper Level, Convention Center
Journal: Cancer Discovery

Novel WRN helicase inhibitors selectively target microsatellite unstable cancer cells

Session: MS.ET09.02 – Novel Antitumor Agents 5, 2:30 – 4:15 p.m. PT
Location: Ballroom 6 DE, Upper Level, Convention Center
Journal: Cancer Discovery

POSTER PRESENTATIONS

Immune-competent “NoGlow” transgenic mice overcome restrictive tolerance to multiple xenoantigens and simultaneously permit identification, tracking, and temporal gene expression in tumor cells

Session: PO.IM02.01 – Adaptive Immunity in Tumors, 9 a.m. – 12:30 p.m. PT
Location: Poster Section 1, Board 27, Presentation 3985
Journal: Cancer Research Communications

Detection of status of cancer in radiology notes using artificial intelligence

Session: PO.CL10.03 – Artificial Intelligence and Data Science on Real World Data, 9 a.m. – 12:30 p.m. PT
Location: Poster Section 38, Board 1, Presentation 4965
Journal: Cancer Research Communications

Randomized phase II trial of imiquimod with or without 9vHPV vs observation in patients with CIN 2 and 3

Session: PO.IM01.08 – Vaccines, Antigens, and Antigen Presentation 1, 9 a.m. – 12:30 p.m. PT
Location: Poster Section 5, Board 15, Presentation 4104
Journal: Clinical Cancer Research

SMAD3 mediates oxaliplatin resistance in esophageal adenocarcinoma

Session: PO.ET02.04 – Drug Combinations, 9 a.m. – 12:30 p.m. PT
Location: Poster Section 23, Board 14, Presentation 4559
Journal: Clinical Cancer Research

Unleashing natural IL-18 activity using an anti-IL-18BP blocker antibody induces potent immune stimulation and anti-tumor effects

Session: PO.IM01.19 – Immune Modulation with Cytokines, 9 a.m. – 12:30 p.m. PT
Location: Poster Section 4, Board 16, Presentation 4072
Journal: Cancer Immunology Research

Inhibition of NEK2 promotes chemosensitivity and reduces primary effusion lymphoma burden

Session: PO.ET01.04 – Mechanisms of Drug Resistance and Novel Combinations, 9 a.m. – 12:30 p.m. PT
Location: Poster Section 25, Board 12, Presentation 4614
Journal: Cancer Research Communications

CB307: A dual targeting costimulatory Humabody® VH therapeutic for treating PSMA-positive tumors

Session: PO.IM01.17 – Immune Modulation Employing Agonist or Co-Stimulatory Approaches, 1:30 - 5 p.m. PT
Location: Poster Section 3, Board 22, Presentation 5313
Journal: Clinical Cancer Research

Nicotinamide in combination with EGFR-TKIs for the treatment of stage IV lung adenocarcinoma with EGFR mutations: A randomized double-blind (Phase IIb) trial

Session: PO.CT02.02 – Phase II Clinical Trials 2, 1:30 - 5 p.m. PT
Location: Poster Section 48, Board 11, Presentation 252
Journal: Clinical Cancer Research

Preclinical development of CAR T cells with antigen-inducible IL-18 enforcement to treat GD2-positive solid cancers

Session: PO.CL06.02 – Adoptive Cellular Therapy 2, 1:30 - 5 p.m. PT
Location: Poster Section 40, Board 19, Presentation 6328
Journal: Clinical Cancer Research

St. Jude Survivorship Portal: Sharing and analyzing large clinical and genomic datasets from pediatric cancer survivors

Session: PO.CL07.03 – Pediatric Clinical Research and Late Effects, 1:30 – 5 p.m. PT
Location: Poster Section 42, Board 16, Presentation 6385
Journal: Cancer Discovery

MILIP drives triple-negative breast cancer through complexing with transfer RNAs to promote protein production

Session: PO.MCB10.03 – microRNAs and Other Non-coding RNAs as Cancer Genes 2, 1:30 – 5 p.m. PT
Location: Poster Section 17, Board 18, Presentation 5697
Journal: Cancer Research

Discovery of a long half-life AURKA inhibitor to treat MYC-amplified solid tumors as a monotherapy and in combination with everolimus

Session: PO.ET02.05 – Cancer Treatment: New Technologies, 1:30 – 5 p.m. PT
Location: Poster Section 22, Board 15, Presentation 5806
Journal: Molecular Cancer Therapeutics

Flash proton radiotherapy mitigates radiation-induced salivary gland dysfunction and oral mucositis in mice

Session: PO.ET08.02 – Radiation, Theranostics, Radiotheranostics, Normal Tissue, and Cellular Stress, 1:30  – 5 p.m. PT
Location: Poster Section 29, Board 18, Presentation 6036
Journal: Molecular Cancer Therapeutics

ZNF397 loss triggers TET2-driven epigenetic rewiring, lineage plasticity, and AR-targeted therapy resistance

Session: PO.ET03.03 – Mechanisms of Drug Resistance 3, 1:30  – 5 p.m. PT
Location: Poster Section 24, Board 22, Presentation 5878

Journal: Cancer Discovery

---

WEDNESDAY, APRIL 10

POSTER PRESENTATION

A real-world toxicity-atlas shows that adverse events of combination-therapies commonly result in additive interactions

Session: PO.ET07.01 – Pharmacology and Pharmacogenetics, 9 a.m. – 12:30 p.m. PT
Location: Poster Section 24, Board 10, Presentation 7169
Journal: Clinical Cancer Research